IceCure Medical Ltd Price, Forecast, Insider, Ratings, Fundamentals & Signals

Data presentation at highly influential american society of breast surgeons ("asbrs") annual meeting by dr. richard fine wins scientific impact award as voted by breast surgeons  president-elect of the asbrs, dr. michael berry, presents data and states "cryoablation is ready for prime time"  company seeks indication for treating women with early stage t1 invasive breast cancer with adjuvant hormone therapy  available reimbursement code for facility expense expected to enhance usage upon receiving marketing authorization minimally-invasive prosense® cryoablation offers highly favorable healthcare economics  caesarea, israel , april 15, 2024 /prnewswire/ -- icecure medical ltd. (nasdaq: iccm) ("icecure" or the "company"), developer of the prosense® system, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it has submitted final data to the u...

Conference call to be held today at 10:00 am eastern time; focus on u.s. market for prosense® in breast cancer indication caesarea, israel , april 3, 2024 /prnewswire/ -- icecure medical ltd. (nasdaq: iccm) ("icecure" or the "company"), developer of the prosense® system, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported sales as of and for the twelve months ended december 31, 2023 increased 26% compared to the twelve months ended december 31, 2022, as the company continues to transition from a research and development and clinical phase company to a commercial phase company.

Continuous innovation as a global leader in minimally invasive liquid-nitrogen based cryoablation systems caesarea, israel , april 2, 2024 /prnewswire/ -- icecure medical ltd. (nasdaq: iccm) ("icecure" or the "company"), developer of the prosense® system, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has filed a 510(k) submission with the united states food and drug administration ("fda") for clearance of its next-generation single probe cryoablation system, the xsense™ system and cryoprobes.

Overview of u.s. commercial strategy will be discussed on conference call caesarea, israel , march 27, 2024 /prnewswire/ -- icecure medical ltd. (nasdaq: iccm) ("icecure" or the "company"), developer of the prosense® system, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the twelve months ended december 31, 2023 before the nasdaq stock market opens on wednesday, april 3, 2024.

Expects to submit full dataset to the fda in april for marketing authorization of prosense® for minimally invasive treatment of early-stage breast cancer study represents largest cryoablation study of its kind in the u.s. for early-stage low-risk malignant breast tumors caesarea, israel , march 19, 2024 /prnewswire/ -- icecure medical ltd. (nasdaq: iccm) ("icecure" or the "company"), developer of the prosense® system, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced positive topline results from the company's ice3 study, the largest controlled multicenter clinical trial ever performed for liquid nitrogen (ln2) based cryoablation of low-risk, early-stage malignant breast tumors, following the 5-year follow-up evaluation of the ice3 study's last patient.

IceCure Medical (ICCM) submits final ICE data along with multiple sub-analysis to the FDA seeking approval for marketing authorization for treating early-stage breast cancer.

IceCure Medical Ltd. (NASDAQ:ICCM ) Q4 2023 Earnings Conference Call April 3, 2024 10:00 AM ET Company Participants Michael Polyviou - EVC Group, Investor Relations Eyal Shamir - Chief Executive Officer Shad Wood - VP of Sales, North American Tlalit Bussi Tel-Tzure - VP of Business Development and Global Marketing Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Conference Call Participants Kemp Dolliver - Brookline Capital Markets Yi Che - H.C.

I've long thought it to be worth diving into the world of medical device stocks. The problem is, there are a myriad of options to choose from, with many companies trading in the small- or micro-cap category.

IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.09 per share in line with the Zacks Consensus Estimate.

CAESAREA, Israel , Nov. 8, 2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the nine months ended September 30, 2023 before the Nasdaq Stock Market opens on Wednesday, November 15, 2023 and also discuss such results and other corporate developments on a conference call at 10:00 a.m.

Growing body of evidence-based data is giving women a minimally invasive alternative to the standard of care lumpectomy Patients throughout the European Union have access to ProSense for the treatment of malignant and benign breast tumors CAESAREA, Israel , Sept. 22, 2023 /PRNewswire/ -- IceCure Medical Ltd.

IceCure Medical Ltd (NASDAQ:ICCM ) Q2 2023 Earnings Conference Call August 14, 2023 10:00 AM ET Company Participants Todd Kehrli - EVC Group, Investor Relations Eyal Shamir - Chief Executive Officer Ronen Tsimerman - Chief Financial Officer and Chief Operating Officer Robert Ward - ProSense User, Assistant Professor, Diagnostic Imaging, Warren Alpert Medical School of Brown University and Program Director, Breast Imaging Fellowship, Associate Chief of Diagnostic Imaging at Women & Infants Hospital Conference Call Participants Anthony Vendetti - Maxim Group Benjamin Haynor - Alliance Global Partners Kemp Dolliver - Brookline Capital Jake Sekelsky - H.C. Wainwright Operator Good morning and thank you for standing by.

IceCure Medical Ltd (NASDAQ:ICCM ) Q1 2023 Earnings Conference Call May 22, 2023 10:00 AM ET Company Participants Todd Kehrli - EVC Group, IR Eyal Shamir - Chief Executive Officer Tlalit Bussi Tel-Tzure - Vice President, Business Development and Global Marketing Ronen Tsimerman - Chief Financial Officer and COO Conference Call Participants Chait G - H.C. Wainwright Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Operator Good morning and thank you for standing by.

IceCure Medical Ltd (NASDAQ:ICCM ) Q4 2023 Earnings Conference Call March 29, 2023 10:00 AM ET Company Participants Eyal Shamir - CEO Ronen Tsimerman - CFO & COO Todd Kehrli - EVC Group, IR Conference Call Participants Kemp Dolliver - Brookline Capital Markets Ben Haynor - Alliance Global Partners Chaitanya G. - H.C. Wainwright Operator Good morning, and thank you for standing by.

While some financial advisors may recommend a small portion of their clients' portfolios to be directed toward higher-risk ventures, hardly any will suggest speculative penny stocks. Suffering from technical issues such as low volume and extremely high volatility, this segment of the capital markets won't be for everyone.